Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04067583
Other study ID # 20285
Secondary ID
Status Completed
Phase
First received
Last updated
Start date October 8, 2019
Est. completion date April 23, 2020

Study information

Verified date April 2021
Source Bayer
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

With this follow up physician survey researcher want to collect the same data from all participants of the study using a highly structured questionnaire. The questionnaire will gather information related to physician characteristics and experience with Aflibercept, as well as assess physicians' knowledge and understanding of storage and preparation, proper injection technique, and the risks associated with Aflibercept injection into the eye (intravitreal injection). Analysis will be done using descriptive statistics.


Recruitment information / eligibility

Status Completed
Enrollment 454
Est. completion date April 23, 2020
Est. primary completion date April 15, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Has signed informed consent - Is a licensed and practicing ophthalmologist - Has prescribed and/or administered aflibercept to at least one patient in the past 6 months Exclusion Criteria: - None

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Physician questionnaire
This is a one-time cross-sectional survey of physicians, conducted electronically; there are no in person visits

Locations

Country Name City State
Germany Many locations Multiple Locations

Sponsors (1)

Lead Sponsor Collaborator
Bayer

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of physicians responding correctly to each individual knowledge question Up to 1 year
See also
  Status Clinical Trial Phase
Completed NCT01447043 - Study to Assess the Effectiveness of Existing Anti vascUlar Endothelial Growth Factor (Anti VEGF) in Patients With Wet Age-related Macular Degeneration (wAMD) (AURA) N/A